Study 56 of 57Semaglutide literaturebiorxiv-preprint · Observational

Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study

Lower doses of compounded semaglutide may achieve significant weight loss when combined with behavioral programs, reaching 91% of the weight loss seen with higher doses in 16 weeks.

Read at biorxiv-preprint Add to compare

Where it sits

this study against the rest of the semaglutide corpus

Preclinical

Observational · this one

Open-label

Randomised

Reviews

Summary and findings

This study evaluated the efficacy of a lower dose of compounded semaglutide in conjunction with a behavioral weight management program over 16 weeks. Participants included users of Noom Weight, Noom Microdose GLP-1 Rx Program, and Noom GLP-1 Rx Program. Weight loss results showed NMGP users lost 8.3% and NGP users lost 8.6% of their baseline weight.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →

At 16 weeks, NMGP users lost 8.3% of their baseline weight.

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>Objective</h4> This 16-week, real-world retrospective cohort study of a behavioral weight management program evaluated the efficacy of a lower dose of compounded semaglutide on weight loss. <h4>Methods</h4> Weight loss was compared among Noom Weight (NW) users, Noom Microdose GLP-1 Rx Program (NMGP) users prescribed a low dose of compounded semaglutide (up to 0.6mg/weekly), and Noom GLP-1 Rx Program (NGP) users prescribed a dose up to 1.2mg/weekly of compounded semaglutide via multiple-group latent growth curve models for the full sample and propensity score matched cohort. Users were matched on demographic characteristics, Area Deprivation Index, baseline Body Mass Index, and urbanicity. <h4>Results</h4> In the full sample, participants (N = 29,788) were mostly middle-aged, urban-dwelling females. At 16 weeks, NW users lost 2.6%, NMGP users lost 8.3%, and NGP users lost 8.6% of their baseline weight (all comparisons p ≤ .001). In the matched cohort (N = 3,657; n= 1,219 per group), participant characteristics were similar. At 16 weeks, NW users lost 2.6%, NMGP users lost 8.3%, and NGP users lost 9.1% of their initial weight (all comparisons p < .001). <h4>Conclusions</h4> This large, retrospective cohort reports lower doses of compounded semaglutide alongside a behavioral companion achieve 91% of the weight loss of a higher dose of compounded semaglutide in the first 16 weeks.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Semaglutide corpus

DSemaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trialsbiorxiv-preprint · Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.review BSide effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective studybiorxiv-preprint · 34% lower relative odds of reporting GI side effects by week 16, p=0.001, n=2,481 per group.Human BA study on risk factors for the progression from T2DM to end-stage renal disease based on Mendelian randomization and logistic regression analysis.Renal failure · 2026 · n=875 · AUC of the logistic regression-based nomogram was 0.88 (95% CI: 0.85-0.91).Human BFeasibility and acceptability of an everyday patient-centered discussion model for primary care: An exploratory, single-center study in the VA primary care setting.PEC innovation · 2026 · n=23 · Mean SDM-Q-9 score was 90.9 out of 100.Human BOral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic Interventionsbiorxiv-preprint · 2026 · 8.69% of GLP-1 users developed at least one newly documented oral-health condition.Human COral Semaglutide Preserves Islet of Langerhans Structure and Cellular Integrity in a Type 2 Diabetes Mellitus Rat Model: Histological, Immunohistochemical, and Biochemical Studybiorxiv-preprint · 2026 · P < 0.05 for islet size, β-cell mass, and insulin immunoreactivity.Animal